Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard A Alm

Showing results (11-20 of 41) with videos related to

Pageof 5
Sort By:
The Journal of Antimicrobial Chemotherapy|July 3, 2014
Activity of avibactam against Enterobacter cloacae producing an extended-spectrum class C β-lactamase enzymeSushmita D Lahiri, Robert A Giacobbe, Michele R Johnstone, et al.
The Journal of Antimicrobial Chemotherapy|July 13, 2016
Structural and sequence analysis of class A β-lactamases with respect to avibactam inhibition: impact of Ω-loop variationsSushmita D Lahiri, Patricia A Bradford, Wright W Nichols, et al.
The Lancet. Microbe|March 30, 2026
WHO assessment of the preclinical antifungal pipeline: evaluating innovation and preparedness in the face of emerging fungal threatsValeria Gigante, Richard A Alm, Tamarie Rocke, et al.
The Lancet. Microbe|October 25, 2024
Addressing urgent priorities in antibiotic development: insights from WHO 2023 antibacterial clinical pipeline analysesDaniela Melchiorri, Tamarie Rocke, Richard A Alm, et al.
Microbiology (Reading, England)|November 13, 2002
Identification of strain-specific genes located outside the plasticity zone in nine clinical isolates of Helicobacter pyloriGrettel Chanto, Alessandra Occhialini, Nathalie Gras, et al.
The Journal of Antimicrobial Chemotherapy|June 6, 2015
Molecular characterization of MRSA isolates bracketing the current EUCAST ceftaroline-susceptible breakpoint for Staphylococcus aureus: the role of PBP2a in the activity of ceftarolineSushmita D Lahiri, Robert E McLaughlin, James D Whiteaker, et al.
Antimicrobial Agents and Chemotherapy|July 2, 2014
High in vitro activity of the novel spiropyrimidinetrione AZD0914, a DNA gyrase inhibitor, against multidrug-resistant Neisseria gonorrhoeae isolates suggests a new effective option for oral treatment of gonorrheaSusanne Jacobsson, Daniel Golparian, Richard A Alm, et al.
ACS Infectious Diseases|August 4, 2021
The CARB-X Portfolio of Nontraditional Antibacterial ProductsErin M Duffy, Ed T Buurman, Su L Chiang, et al.
The Journal of Antimicrobial Chemotherapy|April 30, 2014
Analysis of Staphylococcus aureus clinical isolates with reduced susceptibility to ceftaroline: an epidemiological and structural perspectiveRichard A Alm, Robert E McLaughlin, Veronica N Kos, et al.
The Journal of Antimicrobial Chemotherapy|November 2, 2017
Ceftaroline efficacy against high-MIC clinical Staphylococcus aureus isolates in an in vitro hollow-fibre infection modelRenu Singh, Mashal Almutairi, Richard A Alm, et al.
Pageof 5

Showing results (11-20 of 41) with videos related to

Sort By:
Pageof 5
The Journal of Antimicrobial Chemotherapy|July 3, 2014
Activity of avibactam against Enterobacter cloacae producing an extended-spectrum class C β-lactamase enzymeSushmita D Lahiri, Robert A Giacobbe, Michele R Johnstone, et al.
The Journal of Antimicrobial Chemotherapy|July 13, 2016
Structural and sequence analysis of class A β-lactamases with respect to avibactam inhibition: impact of Ω-loop variationsSushmita D Lahiri, Patricia A Bradford, Wright W Nichols, et al.
The Lancet. Microbe|March 30, 2026
WHO assessment of the preclinical antifungal pipeline: evaluating innovation and preparedness in the face of emerging fungal threatsValeria Gigante, Richard A Alm, Tamarie Rocke, et al.
The Lancet. Microbe|October 25, 2024
Addressing urgent priorities in antibiotic development: insights from WHO 2023 antibacterial clinical pipeline analysesDaniela Melchiorri, Tamarie Rocke, Richard A Alm, et al.
Microbiology (Reading, England)|November 13, 2002
Identification of strain-specific genes located outside the plasticity zone in nine clinical isolates of Helicobacter pyloriGrettel Chanto, Alessandra Occhialini, Nathalie Gras, et al.
The Journal of Antimicrobial Chemotherapy|June 6, 2015
Molecular characterization of MRSA isolates bracketing the current EUCAST ceftaroline-susceptible breakpoint for Staphylococcus aureus: the role of PBP2a in the activity of ceftarolineSushmita D Lahiri, Robert E McLaughlin, James D Whiteaker, et al.
Antimicrobial Agents and Chemotherapy|July 2, 2014
High in vitro activity of the novel spiropyrimidinetrione AZD0914, a DNA gyrase inhibitor, against multidrug-resistant Neisseria gonorrhoeae isolates suggests a new effective option for oral treatment of gonorrheaSusanne Jacobsson, Daniel Golparian, Richard A Alm, et al.
ACS Infectious Diseases|August 4, 2021
The CARB-X Portfolio of Nontraditional Antibacterial ProductsErin M Duffy, Ed T Buurman, Su L Chiang, et al.
The Journal of Antimicrobial Chemotherapy|April 30, 2014
Analysis of Staphylococcus aureus clinical isolates with reduced susceptibility to ceftaroline: an epidemiological and structural perspectiveRichard A Alm, Robert E McLaughlin, Veronica N Kos, et al.
The Journal of Antimicrobial Chemotherapy|November 2, 2017
Ceftaroline efficacy against high-MIC clinical Staphylococcus aureus isolates in an in vitro hollow-fibre infection modelRenu Singh, Mashal Almutairi, Richard A Alm, et al.
Pageof 5